You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. IGF OT IGF TRANSCATHETER CAVOPULMONARY BYPASS ENDOGRAFT SBIR TOPIC DIRECT TO PHASE II IGF OT IGF

    SBC: TRANSMURAL SYSTEMS LLC            Topic: NHLBI

    Extra anatomic bypass or vascular shunts divert blood flow In congenital heart disease these surgical procedures are critical for management Children born with one functional ventricle or cardiac pumping chamber require two to three major cardiac surgery procedures for palliation The management goal is to divert systemic venous return deoxygenated blood from the heart directly to pulmonary a ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. IGF OT IGF MULTIPLEXED HIGH CONTENT ASSAY FOR TOXICITY MECHANISMS AND PHENOTYPES IN LIVE IPSC DERIVED CARDIAC CELLS

    SBC: CAIRN BIOSCIENCES INC            Topic: NIDA

    Toxicological assessments rely on low throughput costly animal studies that deliver minimal insights into compound toxicity mechanisms Induced pluripotent stem cells iPSCs are positioned to transform the evaluation of toxic compounds by enabling predictive physiologically relevant model systems compatible with high throughput screening Combining these iPSC benefits with high content screenin ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. IGF OT IGF SBIR PHASE I TOPIC CTDNA DIAGNOSTIC ENABLED BY MAGNETIC AUTOMATION ASSAYS

    SBC: NVIGEN            Topic: NCI

    Circulating tumor DNA ctDNA is a promising biomarker for noninvasive diagnostic prognostic and follow up tests for cancer However the relatively low quantity of ctDNA and the rare cancer mutations within large excess of wild type DNAs have presented many challenges for its application in the clinic The goal of the research is to develop our magnetic nanobeads and highly fluorescent magnet ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. IGF OT IGF PROXIMITY DNA EXCHANGE IMAGING

    SBC: Ultivue, Inc.            Topic: NCI

    A great challenge in microscopic imaging of biological and medical samples e g tissue sections is to achieve high sensitivity high specificity high multiplexing and high resolution preferably beyond the diffraction limit simultaneously This SBIR proposal addresses this challenge by developing a novel technology platform called Proximity DNA Exchange Imaging As a result of the studies pro ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. IGF OT IGF QUANTUM DOT FRET IMMUNOASSAY TO QUANTIFY INTRAMOLECULAR EPITOPES OF ANALYTES IN TISSUE SECTIONS

    SBC: Ocean Nanotech LLC            Topic: NCI

    Proximity technology motivated by an array of potential applications offers a robust foundation for the development of cell type specific quantitative intramolecular epitopes of analytes in tissue sections In this proposal we highlight how our CamelTM dual peaks quantum dots QDs are greatly suitable fluorophores with spectroscopic properties that can be controlled via fluorescence resonance ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. IGF OT IGF RandD BIOMEDICAL RESEARCH

    SBC: GINER INC            Topic: NCI

    The availability of liquid biopsies such as sampling of blood to measure key disease biomarkers could aid in the detection of blood circulating tumor DNA ctDNA known to confer resistance to cancer therapy For example the T M mutation in the epidermal growth factor EGFR accounts for of acquired resistance to FDA approved EGFR targeted therapies Detection of this mutation is important ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. IGF OT IGF PREDICTIVE BIOMARKERS OF ADVERSE REACTIONS TO RADIATION TREATMENT POP

    SBC: DiaCarta, Inc.            Topic: NCI

    In different individuals exposed to radiation radiation will cause variable levels of rapid combined tissue death cell apoptosis and necrosis leading to toxicity This acute tissue loss correlates with radiation injury DiaCarta sRadTox QuantiDNATMdiagnostic product measures tissue loss and is related to radiation dose field size knownsensitive organ exposure and use of sensitizers RadTox Qua ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. IGF OT IGF TOPIC CANCER PATIENT COGNITIVE ASSESSMENT PLATFORM

    SBC: CHARLES RIVER ANALYTICS, INC.            Topic: NCI

    Cancer survivors commonly report cognitive impairments following chemotherapy With a growing number of cancer survivors comes an increased urgency to better understand the precise etiology and prevalence of cognitive changes associated with cancer and cancer treatment This pursuit is impeded by a lack of assessment tools that can accurately detect the full scope of cognitive deficits To address ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. IGF OT IGF SBIR PHASE I TOPIC CFNA TEMPO SEQ ASSAY

    SBC: Biospyder Technologies, Inc.            Topic: NCI

    We propose to demonstrate the feasibility of a novel highly multiplexed targeted sequencing based Liquid Biopsy TempO Seq Assay to measure cell free circulating DNA cfNA from plasma samples the cfNA TempO Seq assay We will exploit the single base specificity of TempO Seq to measure SNVs and other mutations and measure microsatellite short tandem repeats and methylation with modifications to th ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. IGF OT IGF TITLE A MUCOSAL PROPHYLACTIC VACCINE AGAINST COCCIDIOIDOMYCOSIS

    SBC: Applied Biotechnology Institute, Inc.            Topic: NIAID

    To develop a coccidiomycosis vaccine

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government